The exhaustion of perimenopause is so profound that the idea of a supplement that targets cellular energy at its source feels almost too good to pass up. That's exactly why this category deserves more scrutiny, not less — because women in this season of life deserve real answers, not expensive hope.
Learn more about Rose →Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell of the body, essential for converting food into usable energy and for activating proteins called sirtuins that regulate DNA repair and inflammation. Tissue NAD+ levels measurably decline from around age 40 onward, a finding replicated across multiple human and animal studies. This decline is not marketing fiction — it is real biology, which is precisely why the supplement industry has built an entire category around it.
NAD+ itself is a large, unstable molecule that does not survive intact through the digestive tract or cross cell membranes efficiently, which is why supplements use precursor molecules instead. The two most commonly sold precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), which the body converts into NAD+ intracellularly. This is a genuinely important distinction: when a product is labeled "NAD+" rather than NMN or NR, it may not be delivering what the name implies.
Several small but well-designed human clinical trials have confirmed that oral NMN and NR supplementation does successfully raise NAD+ levels in blood and some tissues, which is an important proof-of-concept step. A 2021 study published in Science found that NMN raised blood NAD+ levels dose-dependently in healthy adults over 65. Raising blood NAD+ is not the same as producing clinical benefits, but it does confirm the mechanism is plausible rather than purely theoretical.
Human RCTs on NMN and NR for energy, fatigue, and physical performance have generally shown modest improvements, often in older adults or people with specific metabolic conditions rather than healthy midlife women. A 2022 trial of NMN in older adults showed small improvements in gait speed and muscle strength, while NR studies show mixed results on subjective energy. The dramatic energy restoration described in supplement marketing is not what the clinical data actually shows, and women with perimenopause-related fatigue should not expect that outcome.
This is perhaps the most important gap to understand: as of 2024, no published RCTs have specifically enrolled perimenopausal or postmenopausal women to test whether NMN or NR improves menopause-specific symptoms such as hot flushes, brain fog, sleep disruption, or mood changes. Extrapolating from general aging-population data to menopausal symptoms is a significant scientific leap. Women deserve to know they are paying for a hypothesis, not a proven solution for their specific experience.
Research published in Nature Metabolism in 2020 demonstrated that estrogen signaling influences NAD+ biosynthesis in cells, and that the enzyme NAMPT — a key regulator of NAD+ production — is partly estrogen-dependent. This means that falling estrogen levels during perimenopause may contribute to the age-related NAD+ decline, which is a genuinely compelling scientific connection. However, whether supplementing NAD+ precursors can compensate for estrogen loss in any meaningful clinical sense has not been tested in humans.
Short-term human trials have found NMN and NR to be well-tolerated at standard doses, with nausea and flushing reported occasionally at higher doses. One area of legitimate ongoing scientific debate is whether chronically elevated NAD+ could theoretically influence cancer cell metabolism, given that cancer cells also rely heavily on NAD+; this has not been demonstrated as a clinical harm in human trials but remains an open research question. Anyone with a personal or family history of cancer should discuss this with their doctor before supplementing.
Exercise, particularly resistance training and high-intensity interval training, activates AMPK and SIRT1 pathways that upregulate the body's own NAD+ biosynthesis — essentially doing from the inside what precursor supplements attempt from the outside. Caloric restriction and time-restricted eating have also been shown to increase NAD+ levels via NAMPT activation in multiple human studies. These are not alternatives being dismissed — they are evidence-based interventions that influence the same molecular targets, often with additional proven benefits for menopause symptoms.
The best-studied doses in human trials range from 250mg to 500mg daily for NR and 250mg to 500mg for NMN, taken in the morning with food; higher doses have not consistently shown proportionally greater benefit and increase both cost and the chance of mild side effects. Because the supplement industry is not tightly regulated in most countries, third-party tested products with a Certificate of Analysis are a more reliable choice than brand reputation alone. A trial period of 8 to 12 weeks with an honest assessment of any change in energy, sleep, or cognitive clarity — tracked simply before and after — gives a more realistic basis for deciding whether to continue.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.